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Summary Retrospectively we analysed postoperative AED treatment in patients with
mesial temporal lobe epilepsy and hippocampal sclerosis (MTLE-HS) who were seizure
free following selective amygdalohippocampectomy (AHE). In this subgroup, we com-
pared the patients without AEDs with that in the entire series. Results: During the
year prior to surgery, in the MTLE-HS group, a mean of 2.3± 0.8 AEDs were taken. The
percentage of seizure-free MTLE-HS patients without AEDs increases to 40% from the
postoperative year 5 on. In the ILAE Class 1a (seizure- and aura-free since surgery) at
postoperative year 5 more than 60% and from postoperative year 7 on more than 90%
have discontinued AED intake. Conclusion: These ﬁgures indicate that reduction and
discontinuation of AEDs is the same in the subgroup ‘‘seizure-free MTLE-HS patients’’
compared to the entire series.
© 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Recently we have reported in great detail the
postoperative seizure outcome and the pre- and
postoperative antiepileptic treatment in patients
who underwent selective amygdalohippocampec-
tomy (sAHE) in Zurich.1,2 Here we report the
year-by-year AED treatment after sAHE in the most
interesting subgroup, i.e. seizure-free patients
with mesial temporal lobe epilepsy (MTLE) and
the histopathology of hippocampal sclerosis (HS).
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We classiﬁed seizure-free patients as ‘‘free of dis-
abling seizures’’, i.e. seizure outcome Engel Class
I3,4 and as ‘‘completely seizure- and aura-free’’,
i.e. ILAE seizure outcome Class 1, and ‘‘completely
seizure- and aura-free since surgery’’, i.e. ILAE
Class 1a.5
Results
The number of patients falling into these three
seizure-free outcome classes year-by-year and the
percentages of patients without AEDs, with AED
mono- and polytherapy are shown in Fig. 1.
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Figure 1 Annual distribution (in %) of seizure-free patients with mesial temporal lobe epilepsy who had hippocampal
sclerosis (HS) following selective amygdalohippocampectomy and antiepileptic drug (AED) intake. Number of patients
falling into seizure outcome Engel Class I (free of disabling seizures), ILAE Class 1 (seizure- and aura-free) and ILAE
Class 1a (seizure- and aura-free since surgery) are given at the top of graphs.
Discussion
There is controversy whether surgical outcome is
different for MTLE with HS (MTLE-HS) compared
to other forms of TLE, although a positive asso-
ciation has been found between the presence of
MTLE-HS, extent of mesial resection and good
seizure outcome. Seizure outcome in MRI-negative
patients and in patients without histopathological
abnormalities in the resected specimen is poor.
The comparison of outcome of MTLE-HS with ‘le-
sion only’ also is controversial, in particular with
a view towards postoperative AED treatment, but
‘lesion’ has to be deﬁned. There are studies sug-
gesting that ‘lesion only’ patients do better than
those with HS alone, and that rate of seizure re-
currence might be higher in MTLE-HS. Other stud-
ies, such as those from UCLA, however, show no
difference less than 5 years after surgery, and
long-term seizure control is even slightly worse
in ‘lesion only’ compared with ‘HS only’ in the
UCLA series. However, the differences of lesion
type have to be taken into account, because some
studies suggest that certain foreign tissue lesions,
such as ganglioglioma and DNET, are associated
with a good to excellent outcome as opposed
to more diffuse dysplasias with a moderate to
poor outcome, depending on the extent of the
resection.
In the Zurich sAHE seizure outcome study1 pa-
tients with MTLE and foreign tissue lesions did bet-
ter than MTLE-HS patients: 5 years after surgery 69%
of patients with foreign tissue lesions versus 63%
with HS were Engel Class I. At postoperative years
10 and 15 the respective percentages are 70 and
64% for foreign tissue lesions, compared to 56 and
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54% for MTLE-HS. In this seizure outcome study, the
most striking difference was seen in the percentage
of patients ILAE Class 1a. At postoperative years 5,
10, and 15 the percentages for ILAE 1a were 48, 50,
and 32% for foreign tissue lesions versus 28, 17 and
13% for MTLE-HS.
However, the AED treatment in the subgroup
‘‘seizure-free patients with MTLE-HS following
sAHE’’ compares favourably with the overall
year-by-year AED treatment of the whole series.2 In
the entire series during postoperative years 7—11,
40% or slightly more of patients without disabling
seizures were off AEDs. The same percentage or
even slightly higher percentages are evident from
Fig. 1 in the subgroup ‘‘seizure-free patients with
MTLE-HS following sAHE’’. The same holds true
for the outcome ILAE Class 1a: In the entire sAHE
series we found that from postoperative year 7 on-
wards more than 90% of patients in Class 1a were
without AEDs and comparable ﬁgures are found in
the subgroup ‘‘seizure-free patients with MTLE-HS
following sAHE’’.
Seen together these results show that patients
with MTLE-HS and selective mesial temporal re-
sections experience about the same rate of AED
reduction compared to the entire series with var-
ious different histopathologies, if sAHE results in
seizure freedom.
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